Correlation between imaging features and rEm18 antibodies in alveolar echinococcosis: results from a multicenter study in France.

Date publication

février 2025

Journal

Parasite (Paris, France)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr MINELLO Anne , Pr THIEFIN Gérard

Tous les auteurs :
Simon G, Grenouillet F, Richou C, Delabrousse E, Blagoskonov O, Minello A, Thiefin G, Frentiu E, Wallon M, ,Bresson-Hadni S, Calame P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39918234

Résumé

To correlate imaging features of alveolar echinococcosis (AE) with the antibodies to recombinant Em18 (rEm18AB) at diagnosis and evaluate initial imaging features associated with serologic response, this retrospective study used data from the prospective multicenter EchinoVISTA study (NCT02876146). Imaging and serology were performed at diagnosis and during follow-up. Univariate and multivariate analyses were used to evaluate imaging features associated with the rEm18AB index. Follow-up analyses evaluated the imaging features associated with serologic response (defined as a 50% reduction in the baseline value within 2 years) in non-operated patients treated with albendazole alone.

Mots clés

Albendazole, Alveolar echinococcosis, Magnetic resonance imaging, Positron emission tomography with computed tomography, rEm18-ELISA

Référence

Parasite. 2025 02 7;32:8